Amber Salter1, Robert J Fox2, Gary Cutter3, Ruth Ann Marrie4, Kate E Nichol5, Joshua R Steinerman5, Karry M J Smith5. 1. Washington University in St Louis, St Louis, MO, USA (AS [now at UT Southwestern Medical Center]). 2. Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA (RJF). 3. The University of Alabama at Birmingham, Birmingham, AL, USA (GC). 4. Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada (RAM). 5. Greenwich Biosciences, Inc, Carlsbad, CA, USA (KEN, JRS, KMJS).
Abstract
BACKGROUND: As cannabis products become increasingly accessible across the United States, it is important to understand the contemporary use of cannabis for managing multiple sclerosis (MS) symptoms. METHODS: We invited participants with MS from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry (aged 18 years or older) to complete a supplemental survey on cannabis use between March and April 2020. Participants reported cannabis use, treated symptoms, patterns, preferences, methods of use, and the factors limiting use. Findings are reported using descriptive statistics. RESULTS: Of the 6934 participants invited, 3249 responded. Of the respondents, 31% reported having ever used cannabis to treat MS symptoms, with 20% currently using cannabis. The remaining 69% had never used cannabis for MS symptoms, for reasons including not enough data about efficacy (40%) and safety (27%), and concerns about legality (25%) and cost (18%). The most common symptoms current users were attempting to treat were spasticity (80%), pain (69%), and sleep problems (61%). Ever users (vs never users) were more likely to be younger, be non-White, have lower education, reside in the Northeast and West, be unemployed, be younger at symptom onset, be currently smoking, and have higher levels of disability and MS-related symptoms (all P < .001). CONCLUSIONS: Despite concerns about insufficient safety and efficacy data, legality, and cost, almost one-third of NARCOMS Registry respondents report having tried nonprescription cannabis products in an attempt to alleviate their symptoms. Given the lack of efficacy and safety data on such products, future research in this area is warranted.
BACKGROUND: As cannabis products become increasingly accessible across the United States, it is important to understand the contemporary use of cannabis for managing multiple sclerosis (MS) symptoms. METHODS: We invited participants with MS from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry (aged 18 years or older) to complete a supplemental survey on cannabis use between March and April 2020. Participants reported cannabis use, treated symptoms, patterns, preferences, methods of use, and the factors limiting use. Findings are reported using descriptive statistics. RESULTS: Of the 6934 participants invited, 3249 responded. Of the respondents, 31% reported having ever used cannabis to treat MS symptoms, with 20% currently using cannabis. The remaining 69% had never used cannabis for MS symptoms, for reasons including not enough data about efficacy (40%) and safety (27%), and concerns about legality (25%) and cost (18%). The most common symptoms current users were attempting to treat were spasticity (80%), pain (69%), and sleep problems (61%). Ever users (vs never users) were more likely to be younger, be non-White, have lower education, reside in the Northeast and West, be unemployed, be younger at symptom onset, be currently smoking, and have higher levels of disability and MS-related symptoms (all P < .001). CONCLUSIONS: Despite concerns about insufficient safety and efficacy data, legality, and cost, almost one-third of NARCOMS Registry respondents report having tried nonprescription cannabis products in an attempt to alleviate their symptoms. Given the lack of efficacy and safety data on such products, future research in this area is warranted.
Authors: Laura Weinkle; Christopher H Domen; Ian Shelton; Stefan Sillau; Kavita Nair; Enrique Alvarez Journal: Mult Scler Relat Disord Date: 2018-11-20 Impact factor: 4.339
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Ryan Vandrey; Jeffrey C Raber; Mark E Raber; Brad Douglass; Cameron Miller; Marcel O Bonn-Miller Journal: JAMA Date: 2015 Jun 23-30 Impact factor: 56.272
Authors: S Gustavsen; H B Søndergaard; S R Andresen; M Magyari; P S Sørensen; F Sellebjerg; A B Oturai Journal: Mult Scler Relat Disord Date: 2019-05-16 Impact factor: 4.339
Authors: Tiffany J Braley; Daniel Whibley; Kevin N Alschuler; Dawn M Ehde; Ronald D Chervin; Daniel J Clauw; David Williams; Anna L Kratz Journal: Mult Scler J Exp Transl Clin Date: 2020-09-22
Authors: Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca Journal: Neurology Date: 2019-02-15 Impact factor: 9.910
Authors: Amber Salter; Gary Cutter; Ruth Ann Marrie; Kathryn Nichol; Joshua R Steinerman; Karry M J Smith; Robert J Fox Journal: Neurol Clin Pract Date: 2022-04